ReviewFrontiers in medicine2026
Opportunistic computed tomography assessment of bone, muscle, and adipose tissue: evidence, limitations, and clinical translation.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Routine body computed tomography (CT) contains quantitative information beyond the organ or disease for which the examination was requested. When technically suitable images have already been acquired, vertebral trabecular attenuation, vertebral fractures, skeletal muscle cross-sectional area and attenuation, and visceral and subcutaneous adipose tissue can be assessed without an additional scan or additional radiation exposure. This narrative review separates analytical validity, clinical association and prediction, clinical utility, demonstrated patient benefit, and implementation readiness. Vertebral fracture detection and protocol-specific vertebral attenuation currently have the most direct connection to established osteoporosis pathways, whereas muscle measures provide mainly disease-specific risk information and adipose, longitudinal, combined, and automated applications remain more heterogeneous. CT muscle area is a surrogate for muscle quantity rather than a direct measurement of muscle mass, and CT alone does not diagnose sarcopenia. Visceral adipose tissue area, subcutaneous adipose tissue area, the visceral-to-subcutaneous adipose tissue ratio, adipose attenuation, and longitudinal fat loss are distinct constructs and do not provide CT-only diagnoses of metabolic syndrome, malnutrition, cachexia, or sarcopenic obesity. Recent automated systems show strong technical performance, including external and prospective workflow evaluations, but evidence that routine automated reporting improves patient outcomes remains limited. Combined bone-muscle-adipose assessment is biologically plausible but should currently be regarded as hypothesis-generating unless incremental predictive or clinical value is demonstrated. Translation therefore requires protocol-aware measurement, repeatability assessment, visible quality control, explicit responsibility for verification and follow-up, and prospective evaluation of patient benefit, workload, equity, and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.